Making an in vitro diagnostic assay has never been easy. Now with the global lab and supply chain and disruptions caused by the COVID pandemic, the development and manufacture of IVDs faces further challenges.
Fortunately, the successful commercialization of your assay in these turbulent times and beyond can benefit from some important, often overlooked considerations in design and planning.
Attend the virtual, two-day IVD conference where international technical experts and scientists will address key aspects of IVD immunoassay (CLIA, immunoturbidimetry, qualitative and quantitative lateral flow, etc.) development and performance, including:
Join us to learn about current and future IVD technologies and market trends, both now, and post-COVID from industry leaders, while taking advantage of networking opportunities and a supplier exhibition. We look forward to staying connected with you virtually!
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.